About Samsara BioCapital
Samsara BioCapital is a venture capital firm founded in 2016. It is primarily based out of Palo Alto, United States. As of Sep 2026, Samsara BioCapital is an active investor, having invested in 191 companies, with 10 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Series A round of R1 Therapeutics Overall, Samsara BioCapital portfolio has seen 4 unicorns, 35 IPOs and 35 acquisitions including key companies like Turtlemint, Ping Identity and IQM. A lot of funds co-invest with Samsara BioCapital, with names like RA Capital Management sharing a substantial percentage of its portfolio. Samsara BioCapital has team of 18 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 5 more
Portfolio IPOs
Portfolio Acquisitions
Deals in last 12 months
Samsara BioCapital's List of Top Investments
Samsara BioCapital has a portfolio of 191 companies, including 4 unicorns. Their most notable investments are in Psithera and Normunity.Their portfolio spans across United States, India, United Kingdom and 19 more locations. They have invested in Life Sciences, Enterprise Applications, High Tech and 31 other sectors, across stages such as Series A, Series B and 5 more. Here is the list of top investments by Samsara BioCapital:
1. Turtlemint
Provider of platform for comparing and purchasing insurance, loans, and funds. It offers tools for advisors to manage clients and grow their businesses. The platform provides access to insurance, investment, and credit products. It also delivers training and support for advisors, including product information and sales skills development. The platform further offers solutions for banks, e-commerce businesses, and insurers.
Key facts about Turtlemint
- Founded Year: 2015
- Location: Mumbai (India)
- Annual Revenue: ₹500 - ₹1,000 Cr as on Mar 31, 2025
- Stage: Public
- Total Funding till date: $220M
- Employee Count: 972 as on Mar 31, 2025
- Investors: Marshall Wace, Amansa Capital and 17 Others
- Latest Funding Round: Series E, Apr 29, 2022, $*****
- Highlight: Public
2. Pratilipi
Online self-publishing and storytelling platform offering digital literature in multiple languages. It provides a space for writers to self-publish their works, including stories, poems, articles, and novels. The platform enables readers to discover content, save favorites, listen audiobooks, and interact with writers through reviews and discussions. It fosters a community where writers and readers can connect and share their literary interests.
Key facts about Pratilipi
- Founded Year: 2014
- Location: Bengaluru (India)
- Annual Revenue: ₹50 - ₹100 Cr as on Mar 31, 2025
- Valuation: $*****
- Stage: Series E
- Total Funding till date: $97M
- Employee Count: 201 as on Aug 31, 2025
- Investors: Nexus Venture Partners, Jungle Ventures and 46 Others
- Latest Funding Round: Series E, Apr 03, 2025, $*****
- Highlight: Editors' Pick
Provider of identity security solutions for digital enterprises and organizations. The platform offers flexibility, resilience, and security to meet identity challenges. It helps businesses plug identity into their existing ecosystem. The platform offers capabilities such as orchestration, decentralized identity, and fraud prevention. It also provides solutions for government, financial services, healthcare, retail, and media sectors.
Key facts about Ping Identity
- Founded Year: 2002
- Location: Denver (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2021
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $136M
- Employee Count: 2,375 as on Sep 30, 2026
- Investors: Sprout Capital Partners, Thoma Bravo and 25 Others
- Latest Funding Round: Series E, Sep 18, 2014, $*****
- Highlight: Acquired
4. CityMall
Online marketplace connecting consumers in emerging urban and rural markets with a wide range of grocery, fashion, and home products. It is a digital marketplace that offers a broad assortment of products—including groceries, fashion, and home essentials—through a mobile app and web portal. The platform focuses on consumers in smaller urban and rural markets, providing a convenient online shopping experience tailored to local needs. It operates as a social commerce venture, leveraging community engagement to drive product discovery and purchase decisions.
Key facts about CityMall
- Founded Year: 2019
- Location: Gurugram (India)
- Annual Revenue: ₹500 - ₹1,000 Cr as on Mar 31, 2025
- Valuation: $*****
- Stage: Series D
- Total Funding till date: $166M
- Employee Count: 1,284 as on May 31, 2026
- Investors: Arena Ventures, Elevation Capital and 56 Others
- Latest Funding Round: Series D, Aug 08, 2026, $*****
- Highlight: Editors' Pick
5. BookMyShow
Online event ticketing platform offering a wide range of entertainment options, including movies, concerts, sports, and plays, enabling users to discover, book, and manage tickets for various events. The platform provides a user-friendly interface for users to browse and book tickets, and also offers features such as showtimes, reviews, and trailers. BookMyShow has expanded its services to multiple countries, including Malaysia, Singapore, and Indonesia, and has become a popular destination for entertainment enthusiasts.
Key facts about BookMyShow
- Founded Year: 1999
- Location: Mumbai (India)
- Annual Revenue: ₹1,000+ Cr as on Mar 31, 2025
- Stage: Series A
- Total Funding till date: $18M
- Employee Count: 652 as on Jul 31, 2025
- Investors: Elevation Capital, Jungle Ventures and 3 Others
- Latest Funding Round: Unattributed, Aug 19, 2026, $*****
- Highlight: Editors' Pick
Samsara BioCapital's Year-on-Year Investment Trends
Samsara BioCapital has invested in 191 companies over the last 9 years, with an average of 8 new investments annually in the last 5 years. In 2025, it made 11 investments, while as of Sep 2026, it has made 12 investments in this year. Its most recent first time investment was in R1 Therapeutics and most recent follow-on round was in Link Cell Therapies.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 7 | 5 | 12 |
2025 | 7 | 4 | 11 |
2024 | 9 | 7 | 16 |
2023 | 4 | 9 | 13 |
2022 | 10 | 8 | 18 |
2021 | 24 | 3 | 27 |
2020 | 19 | 6 | 25 |
2019 | 14 | 0 | 14 |
2018 | 3 | 0 | 3 |
2017 | 2 | 0 | 2 |
Samsara BioCapital's Investments by Stage
Samsara BioCapital has made 33 investments in Series A stage with an average round size of $86.6M, 32 investments in Series B stage with an average round size of $92.8M and 16 investments in Post IPO stage with an average round size of $109M.Stage of entry | No. of Investments |
|---|---|
Series A | 33 |
Series B | 32 |
Post IPO | 16 |
Series C | 8 |
Series D | 6 |
Others | 4 |
Note: We have considered here, only first round of investments
Samsara BioCapital's Investments by Sector
Samsara BioCapital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Sustainability Tech and Enterprise Applications. Notably, it has invested in 167 Tech companies, 155 Enterprise (B2B) companies, 56 Software companies and at least 33 companies focusing on Saas.Sector | No. of Investments |
|---|---|
Life Sciences | 92 |
High Tech | 12 |
HealthTech | 4 |
Sustainability Tech | 4 |
Enterprise Applications | 3 |
Others | 4 |
Note: We have considered here, only first round of investments
Samsara BioCapital's Investments by Geography
Samsara BioCapital has made most investments in United States (80), followed by United Kingdom where it has made 7 investments.Country | No. of Investments |
|---|---|
United States | 80 |
United Kingdom | 7 |
Canada | 3 |
France | 2 |
Austria | 1 |
Others | 4 |
Note: We have considered here, only first round of investments
Samsara BioCapital's recent investments
Samsara BioCapital has made 12 investments in 2026 so far. R1 Therapeutics and Link Cell Therapies are the latest among them.Here are the most recent investments by Samsara BioCapital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 30, 2026 | United States | Series A | 6621 | [+5] | |
Sep 29, 2026 | United States | Series A | 4272 | ||
Aug 07, 2026 | United States | Series D | 1099 | ||
Jul 28, 2026 | United States | Series B | 5871 | ||
Jun 22, 2026 | United States | Series B | 7363 | [+2] |
Unicorns in Samsara BioCapital's Portfolio
Samsara BioCapital has 4 unicorns in its portfolio - IQM, Creatio, Payhawk and others. The most recent unicorn in their portfolio is IQM. It became a unicorn in 2025, 1 years before Samsara BioCapital first invested in it.Here is a list of unicorns in Samsara BioCapital's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
78 | Developer of superconducting quantum computers | 2018 | Espoo | Series B | gxd{qky | ||
67 | Developer of enterprise automation software featuring no-code platform capabilities | 2002 | Boston | Series D | lamuoad | ||
67 | Provider of spend management platform with AI-powered automation and control | 2018 | Sofia | Series B | ucvmguv | ||
77 | B2B e-commerce platform for industrial supplies | 2015 | Singapore | Series F | bewechq |
IPOs and Publicly Listed companies in Samsara BioCapital's Portfolio
35 of Samsara BioCapital's portfolio companies have become public. Obsidian Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Aug 2026 and Turtlemint got listed on the Bombay Stock Exchange (BSE), National Stock Exchange (NSE) at marketcap of $471M.Here are Samsara BioCapital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 04, 2026 | Sep 09, 2021 | Series B | 2093 | |
Jun 29, 2026 | - | - | 8011 | |
Jun 10, 2026 | Mar 01, 2024 | Series E | 2547 | |
Apr 17, 2026 | Sep 08, 2021 | Series B | 2608 | |
Feb 06, 2026 | Jul 10, 2023 | Series C | 6011 |
Acquired companies in Samsara BioCapital's Portfolio
35 companies from Samsara BioCapital's portfolio have been acquired. The most recent acquisition was Candid Therapeutics in May 2026 by UCB for $*****.Here are Samsara BioCapital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 03, 2026 | Sep 09, 2024 | Series D | 4795 | |
Mar 31, 2026 | Feb 16, 2021 | Series A | 7827 | |
Mar 27, 2026 | Oct 13, 2025 | Series A | 4968 | |
Feb 23, 2026 | Mar 26, 2021 | Series C | 1842 | |
Dec 23, 2025 | - | - | 1199 |
Team profile of Samsara BioCapital
Samsara BioCapital has a team of 18 members including 2 Partners, 10 Venture Partners and 2 Principals located in United States and United Kingdom. Samsara BioCapital's team does not sit on the board of any company as of now.Here is a list of top team members in Samsara BioCapital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Francisco | - | ||
Partner | Redwood City | - | - | |
Venture Partner | Cambridge | - | ||
Venture Partner | New York City | - | ||
Venture Partner | Bourne End | - | ||
Venture Partner | Carlsbad | - | ||
Venture Partner | San Francisco | - | ||
Venture Partner | Lansdale | - | ||
Venture Partner | Palo Alto | - | ||
Venture Partner | San Francisco | - |
Co-investors of Samsara BioCapital
Over the past 9 years, 673 investors have co-invested in Samsara BioCapital's portfolio companies. This includes funds and angels.
- Invested before Samsara BioCapital: Orbimed, HHS and 216 others have invested in rounds before Samsara BioCapital. There are 8 companies where Orbimed has invested before Samsara BioCapital and 7 companies where HHS has invested before Samsara BioCapital.
- Top Co-investors of Samsara BioCapital: 274 investors entered a company along with Samsara BioCapital. These include investors like RA Capital Management (15 companies).
- Invested after Samsara BioCapital: A total of 181 investors have invested in Samsara BioCapital's portfolio after their investments. Top Investors include Janus Henderson Investors (7 companies), RA Capital Management (5 companies) and Orbimed (4 companies).
Recent News related to Samsara BioCapital
•
R1 Therapeutics Secures $80.5 Million to Fund Phase IIb Study for Hyperphosphatemia Treatmenthttps://www.clinicaltrialsarena.com/•Oct 01, 2026•R1 Therapeutics, Samsara BioCapital
•
Abcuro Secures $66 Million Series D Funding for IBM Clinical Trialhttps://www.clinicaltrialsarena.com/•Aug 19, 2026•Abcuro, New Leaf Venture Partners, Bain Capital Life Sciences, Aberdeen Group and 10 others
•
Claris collects $118M to take eye drop into pivotal testing next year - Endpoints NewsGoogle•Jul 28, 2026•Claris Bio, Sofinnova Investments, Novo Holdings, Aisling Capital and 5 others
•
Nura Bio Secures $74M Series B to Advance ALS Drughttps://citybiz.co•Jun 23, 2026•NURA, Euclidean, Sanofi Ventures, Samsara BioCapital and 1 other
•
Artiva lines up $300M as biotech stock sale prices at $11.52Stocktitan•May 08, 2026•Caligan Partners, Venrock, Adage Capital Management, RA Capital Management and 7 others
•
Coultreon Biopharma Secures $125M Series A to Advance Immunology PipelineBioSpace•Apr 28, 2026•Novo Holdings, Forbion, Sofinnova Investments, Finchley Healthcare Ventures and 16 others
•
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for CancerBusiness Wire•Apr 08, 2026•Sidewinder Therapeutics, Frazier Life Sciences, Novartis Venture Fund, Samsara BioCapital and 6 others
•
Colorado biotech Ambrosia lands $100M for oral GLP-1Endpoints•Mar 31, 2026•Ambrosia Biosciences, Blue Owl, Deep Track Capital, Samsara BioCapital and 8 others
•
Coherus Oncology Closes Public Offering of Common StockGlobeNewswire•Feb 18, 2026•Coherus Biosciences, Samsara BioCapital, Janus Henderson Investors, HBM Healthcare Investments
•
Primmune Therapeutics Announces Additional Close of Series B FinancingBenzinga•Jan 26, 2026•Primmune Therapeutics, Samsara BioCapital, Oberland Capital, Bioqube Ventures
